drugset
drugset / Trial / NCT04628793

A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants

NCT04628793 ↗

Phase 1 Completed 29 enrolled Pfizer
RandomizedSequentialDouble-blindBasic science

Summary

This study will be the first time PF-07258669 is administered to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of PF-07258669 following administration of single oral doses to healthy adult participants.

Timeline

Start
2021-03-16
Primary completion
2021-08-25
Completion
2021-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-07258669 Unknown — Oral

Indications

No indication recorded.